Management Team - Albert Yen, M.D.

 

Albert Yen, M.D.

Vice President of Medical Affairs

Dr. Yen is a Physician Scientist with over 10 years of experience in basic and clinical research trial design, medical device commercialization, and small business administration. Prior to joining the Fairway management team, he performed research studies on neurodegenerative conditions at Methodist Hospital Research Institute in the Texas Medical Center and also worked with a proteomics company based in The Woodlands, Texas. He received his medical degree from Baylor College of Medicine and also completed his Neurology residency and Clinical Neurophysiology fellowship training there.  His other research interests include stroke and cerebrovascular disease, traumatic brain injury, primary headache disorders, and urological neuromodulation.

 Dr. Yen currently serves as Fairway’s VP of Medical Affairs, as well as Chairman of the Fairway IACUC (Animal Use and Care Committee). 

Publications:

  1. Digital thermal monitoring (DTM) of vascular reactivity closely correlates with doppler flow velocity. McQuilkin GL, Panthagani D, Metcalfe RW, Hassan H, Yen AA, Naghavi M, Hartley CJ. Conf Proc IEEE Eng Med Biol Soc. 2009;1:1100-3.

  2. Heated underwear garment as a novel complementary treatment for incomplete bladder emptying in patients with bladder outlet obstruction. Yen AA, Naghavi M, Waheed A, Ghazi A, Mobley D. Abstract presented at Western Section – American Urological Association meeting in Las Vegas, Nevada, September 2009.

  3. Heating perineal and suprapubical areas using a modified bidet reduces post-void residual volume in patients with bladder outlet obstruction. Yen AA, Naghavi M, Waheed A, Ghazi A, Mobley D. Abstract presented at Western Section – American Urological Association meeting in Las Vegas, Nevada, September 2009.

  4. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Neurology. 2008 Oct 21;71(17):1326-34.

  5. ALSFRS and Appel ALS scores: discordance with disease progression. Voustianiouk A, Seidel G, Panchal J, Sivak M, Czaplinski A, Yen A, Appel SH, Lange DJ. Muscle Nerve. 2008 May;37(5):668-72.

  6. Mutant SOD1(G93A) microglia are more neurotoxic relative to wild-type microglia. Xiao Q, Zhao W, Beers DR, Yen AA, Xie W, Henkel JS, Appel SH. J Neurochem. 2007 Sep;102(6):2008-19. Epub 2007 Jun 7.

  7. The value of database controls in pilot or futility studies in ALS. Czaplinski A, Haverkamp LJ, Yen AA, Simpson EP, Lai EC, Appel SH. Neurology. 2006 Nov 28;67(10):1827-32.

  8. Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH. Proc Natl Acad Sci U S A. 2006 Oct 24;103(43):16021-6. Epub 2006 Oct 16.

  9. Predictability of disease progression in amyotrophic lateral sclerosis. Czaplinski A, Yen AA, Simpson EP, Appel SH. Muscle Nerve. 2006 Dec;34(6):702-8.

  10. Slower disease progression and prolonged survival in contemporary patients with amyotrophic lateral sclerosis: is the natural history of amyotrophic lateral sclerosis changing? Czaplinski A, Yen AA, Simpson EP, Appel SH. Arch Neurol. 2006 Aug;63(8):1139-43.

  11. Amyotrophic lateral sclerosis: early predictors of prolonged survival. Czaplinski A, Yen AA, Appel SH. J Neurol. 2006 Nov;253(11):1428-36. Epub 2006 Jun 13.

  12. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Goldknopf IL, Sheta EA, Bryson J, Folsom B, Wilson C, Duty J, Yen AA, Appel SH. Biochem Biophys Res Commun. 2006 Apr 21;342(4):1034-9. Epub 2006 Feb 20.

  13. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. Czaplinski A, Yen AA, Appel SH. J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):390-2.

  14. Activated microglia initiate motor neuron injury by a nitric oxide and glutamate-mediated mechanism. Zhao W, Xie W, Le W, Beers DR, He Y, Henkel JS, Simpson EP, Yen AA, Xiao Q, Appel SH. J Neuropathol Exp Neurol. 2004 Sep;63(9):964-77.

  15. AALSS. Yen A, Simpson E, Haverkamp L, Appel S. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:94-8. Review.

  16. Design using historical controls. Yen A, Simpson E, Haverkamp L, Appel S. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:61-3.

  17. HFE mutations are not strongly associated with sporadic ALS. Yen AA, Simpson EP, Henkel JS, Beers DR, Appel SH. Neurology. 2004 May 11;62(9):1611-2.

  18. Oxidative Stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Simpson EP, Yen AA, Appel SH. Curr Opin Rheumatol. 2003 Nov;15(6):730-6. Review.

Book Chapter:

Simpson EP, Yen AA, Appel SH. Amyotrophic Lateral Sclerosis. In: Ikezu T, Gendelman HE, eds. Neuroimmune Pharmacology. New York, NY: Springer; 2008: 377-388.

Patents:

 

20090287069 Methods and Apparatus for Repeated Ischemic Conditioning Treatment of Hypertension and Other Medical Conditions

 

20090177224 Methods and Apparatus for Blood Sampling

 

20090137884 Methods and Apparatus for Repeated Ischemic Conditioning Treatment of Hypertension and Other Medical Conditions

 

20070042429 Assay for differentiating Alzheimer's and Alzheimer's-like disorders

 

20070017809 Assay for ALS and ALS-like disorders

 

20060278532 Assay for neuromuscular diseases

 

20060115867 TRIM 5 related protein as a biomarker of neurodegenerative disease

 

20060115856 2'-5'-oligoadenylate synthetase like protein as a biomarker for neurodegenerative disease

 

20060115855 FK506-binding protein 7 related protein as a biomarker for neurodegenerative disease

 

20060115854 Acetyl-LDL receptor related proteins and peptides as a biomarker for neurodegenerative disease

 

 

 

 

 

 

 
     © 2012 – Fairway Medical Technologies, Inc.